politics 2025 Trump Tariffs on Pharmaceutical Imports Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
category:news Hims pivots to branded Tirzepatide, generic Liraglutide Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
research STRIDE study: GLP1s vs peripheral artery disease (PAD) Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
category:news Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).
company:novo-nordisk Novo Nordisk offers cheaper Wegovy Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:news VK2735's manufacturing alliance with CordenPharma Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735
category:news BRP - a new GLP1-like peptide We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.
company:hims HIMS ends compounded Semaglutide offering Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
chemical:semaglutide Semaglutide removed from shortage list It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
country:mexico Mexico and GLP1s We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
category:news Ozempic approved for Chronic Kidney Disease The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
company:novo-nordisk Novo's Amycretin delivers great Phase 2 results Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
category:news The battle for compounded GLP1 continues The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.
government Government Price negotiations on Ozempic and Wegovy The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:side-effects Pancreatitis and Gallstones after massive weight loss We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
category:news Robert F. Kennedy Jr vs GLP1 RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?
research Research suggesting GLP1 is a brain drug Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.
company:hikma Another Generic Liraglutide launch: Hikma Phamaceuticals A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.
category:news HIMS to offer Liraglutide after shortage rule changes HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?
company:eli-lilly Eli Lilly brands GLP1s as "anti-hedonics" Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"
government Biden-Harris administration keen on GLP1s The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.
country:uk The UK's bet on GLP1 A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.
category:news Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024 At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
category:news FDA reconsidering Tirzepatide shortage list removal After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
category:news Compounders sue FDA over Tirzepatide shortage changes Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
